PaceMate, the cardiac remote monitoring and management platform that leading healthcare providers trust, is taking on the critical task of transitioning a number of health systems and cardiovascular clinics from Philips’ Geneva platform to its cloud-based platform PaceMateLIVE. The migration comes in response to the official end-of-service and support for Philips’ implantable device monitoring platform, which went into effect June 30. Before announcing this to its customers, Philips selected PaceMate as its preferred partner to support healthcare providers across the country in a transition to the PaceMate platform. PaceMate has already successfully migrated more than a dozen Geneva customers within a week, including the University of California San Francisco, and others. 

Healthcare providers that rely on Geneva to monitor and manage data from tens of thousands patients’ implantable cardiac devices now face an urgent need to transition away from the legacy platform without disrupting patient care. For many providers, making the transition to a more modern remote monitoring and management platform was already on their digital transformation roadmaps. But Philips’ decision to end services expedited a pivotal decision that might have otherwise required significant time and resources. 

To best support its customers in this process, Philips identified PaceMate as the best-suited transition partner, citing it as the most comprehensive of all cardiac data management platforms and remote monitoring services. Of particular priority for Philips was ensuring that the platform it endorsed could migrate its users quickly, scale with their growth and ensure undisrupted continuity of patient care during the transition. With PaceMate, healthcare providers will gain more than just a fast migration, stability and scale. Philips has made PaceMate the only device monitoring and management company with access to 100 per cent of its historical patient data and transmissions (other companies only have partial data).

PaceMate will additionally enable healthcare providers to:

Manage all cardiac devices from one unified platform. PaceMate manages data from implantables, wearables, ambulatory, heart failure and consumer ECG devices–bringing more than 150 discrete data points from patients’ devices and EMR records into a single interface. This centralized approach streamlines workflows that have traditionally been spread across multiple different platforms.

Prioritize critical patients through its proprietary Auto-Triage functionality. PaceMate automatically distinguishes between standard manufacturer alerts and truly actionable alerts that require priority attention from clinicians. By integrating device data with EMR data, PaceMate users can additionally create customizable parameters that affect all patients–or apply only to individual patients. 

Integrate with their EHRs in real-time. PaceMate has completed over 700 EHR integrations, the most in the industry, enabling users to integrate with their systems in multiple ways, and in real time.

Automate billing to seamlessly manage clinic reimbursements. PaceMate enables healthcare providers to capture reimbursement for their work with its automated billing and billable reporting. 

Optimize practice performance with analytics. PaceMate’s robust Clinical Management and Practice Management dashboards turn data into actionable insights that enable further improve clinical care, financial, productivity and operational decisions.   

“When a technology like Geneva sunsets, it creates urgency and puts clinicians in a position to have to make a very big decision quickly,” said J.R. Finkelmeier, CEO of PaceMate. “Philips has done its part by delivering a clear recommendation to its customers to make their decision easier. On PaceMate’s end, we’ve made healthcare providers’ transitions seamless, ensuring that clinics maintain full control and continuity of their patients’ care.”